13C-Labeled Narcotic Drug Standards for LC-MS/MS Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for chemical analysis of narcotic drugs face challenges with deuterium labeling, including risk of hydrogen-deuterium exchange, different elution times, and response factor discrepancies, which affect accuracy and reproducibility, and there is a lack of 13C-labeled narcotic drug standards for precise analysis.
Innovation Solution
Development of a test kit containing deuterium-free, 13C-labeled isotopologues of narcotic drugs in sealed vessels for precise and reproducible quantitative determination, allowing for accurate analysis without the risks associated with deuterium labeling and providing reliable standards for chemical analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If deuterium labeling is used for quantitative analysis of narcotic drugs, then internal standards can be obtained, but hydrogen-deuterium exchange occurs during workup procedure affecting accuracy
Solution Approach 1:
The patent changes the isotopic parameter from deuterium (2H) to carbon-13 (13C) labeling. This parameter change eliminates the hydrogen-deuterium exchange problem because carbon atoms do not undergo exchange reactions with hydrogen during workup procedures, thereby maintaining the reliability of the internal standard while preserving measurement precision.
Solution Approach 2:
The patent extracts or removes the problematic deuterium atom from the internal standard structure and replaces it with carbon-13 labeling. This separation of the labeling function from hydrogen-bearing positions eliminates the exchange issue while maintaining the internal standard's ability to provide accurate quantitative data.
2Measurement precision
If deuterium labeled compounds are used as internal standards, then quantitative analysis can be performed, but different elution times occur in GC and LC
Solution Approach 1:
The patent changes the isotopic labeling parameter from deuterium to carbon-13. Since carbon-13 has the same valency and bonding properties as carbon-12, the labeled compounds elute at identical times to their unlabeled counterparts in both GC and LC, eliminating the elution time difference problem while maintaining quantitative analysis capability.
3Measurement precision
If deuterium labeled compounds are used as internal standards, then analysis can proceed, but response factor differs from native compounds
Solution Approach 1:
The patent changes the isotopic label from deuterium to carbon-13. Carbon-13 labeled compounds have identical response factors to their native, unlabeled counterparts because they share the same electronic structure and ionization characteristics, eliminating the response factor discrepancy while preserving quantitative determination ability.
4Reliability
If 13C labeled compounds are used to avoid deuterium exchange, then no exchange risk occurs, but overlap with natural 13C in native compound occurs
Solution Approach 1:
The patent applies local quality by concentrating multiple carbon-13 labels (at least three) at specific strategic positions within the narcotic drug molecule. This localized multiple labeling creates a sufficient mass difference and isotopic pattern that clearly distinguishes the labeled internal standard from the naturally occurring 13C in the native compound, thereby achieving both stability and signal differentiation.
5Measurement precision
If multiple 13C labels are used to overcome natural 13C overlap, then signal differentiation improves, but compound synthesis complexity increases
Solution Approach 1:
The patent applies local quality by concentrating multiple carbon-13 labels (at least three) at specific strategic positions within the narcotic drug molecule. This localized multiple labeling creates a sufficient mass difference and isotopic pattern that clearly distinguishes the labeled internal standard from the naturally occurring 13C in the native compound, thereby achieving both stability and signal differentiation.
Solution Approach 2:
The patent employs preliminary action by incorporating 13C-labeled precursors or building blocks into the synthesis pathway at early stages. This approach allows for efficient incorporation of multiple 13C labels during the synthesis process rather than requiring post-synthesis labeling, thereby reducing overall synthesis complexity while achieving the required isotopic enrichment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The test kit enables highly precise and reproducible quantitative analysis of narcotic drugs, minimizing errors and improving safety and control of handling and transport, while ensuring accurate results through correction of ion suppression and stable isotope labeling.
Implementation Method 1
The 13C isotope labeled internal standards are particularly suitable of minimizing the effects of ion suppression effects in LC-MS/MS analysis
Implementation Method 2
mass spectrometry (MC), tandem mass spectrometry (MC/MC)
Data Source
AI summary
A test kit for the quantitative determination of narcotic drugs comprising (A) series of sealed vessels, each vessel containing a deuterium free isotopologue of a narcotic drug in exactly defined concentrations and quantities, wherein the isotopologue differs from vessel to vessel and—wherein the quantities of the isotopologue differ from vessel to vessel or are the same for all vessels; and/or (B) series of sealed vessels, each vessel containing in exactly defined concentrations and quantities the same isotopologue in quantities which differ from vessel to vessel; wherein the free isotopologues are selected from narcotic drugs; prodrugs, salts, solvates, hydrates and polymorphs and contain at least three stable isotopes selected from the group consisting of 13C, 15N and 18O in the molecule with a degree of labeling of at least 95 mol-%; the use of the test kit and a method for quantitatively determining narcotic drugs.